Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in ...

Windtree Therapeutics, recently made waves by announcing plans to allocate up to $700 million toward acquiring BNB.

Windtree Therapeutics has said it is raising another $520 million to buy up BNB, the fifth-largest digital coin, to put on ...

Windtree Therapeutics' latest move goes beyond its surprising forays into real estate and waste management, as the company ...

The drop came amid a wider market selloff triggered by bitcoin's decline to $112,800, which sparked $360 million in liquidations in 24 hours.

BNB's price rose nearly 2% to top $760, driven by a surge in volume and coordinated buying that pushed through technical ...

Nasdaq-listed biotech company Windtree Therapeutics (WINT) announced it has signed a $500 million equity line of credit (ELOC ...

Biotech firm Windtree plans $520M Binance Coin bet via stock deals and credit line, pending shareholder approval amid mixed ...

WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late ...

WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late ...

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis.

About Windtree Therapeutics Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis.